Noninvasive assessment of characteristics of novel anti-HER2

Por um escritor misterioso

Last updated 11 março 2025

HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

Full article: Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells

Frontiers Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications

Cancers, Free Full-Text

HER2 targeted noninvasive immunosensor based on pencil graphite electrode for detection of breast cancer - ScienceDirect

124I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies

New Approach May Help Predict HER2+ Tumor Response to Treatment – Consult QD

Cancers, Free Full-Text

Biomedicines, Free Full-Text

IJMS, Free Full-Text

Cancers, Free Full-Text

Anti-HER2 monoclonal antibody based-radioimmunoconjugates: Assessment of the chelating agent influence - ScienceDirect

The landscape of d16HER2 splice variant expression across HER2-positive cancers

Recomendado para você